CLOs on the Move

Well and Company

www.wellandcompany.com

 
Well & Company™ is igniting a self care revolution, offering its community members a powerful opportunity to share daily strategies that confront significant health and lifestyle challenges including aging, weight gain, fatigue, sleeplessness, stress, and loneliness. We “Embrace the Day™,” through social selling with our engaging content, innovative products and inspired community.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Raydian Properties

Raydian Properties is passionate about creating a better Elder Living experience — the kind we want for our families. We are proud to be NJ’s largest provider of small group home dementia and Alzheimer’s care. We believe there is life beyond a diagnosis and with the right team, our residents can continue having a meaningful journey of a life worth living. Our homes welcome the flow of life with open kitchen, dining, and living spaces. Everyone who works at Raydian Properties is a Care Partner. We believe fresh, wholesome food nourishes both the mind and body. Care Partners prepare all food on-site and we believe in empowering every Care Partner to create joyful living experiences.

Wright and Filippis

Wright & Filippis is a Rochester Hls, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Minnesota Visiting Nurse Agency

MVNA serves individuals and families that are economically disadvantaged and at high risk for critical social and health issues. More than 90% of MVNA clients residing in Minneapolis are living at or below 200% of Federal Poverty Guidelines. Many of

Redco Group

Redco Group is a Stroudsburg, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Plasmatech Biopharmaceuticals

Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona’s lead program is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. Clinical trials for Sanfilippo types A and B are anticipated to begin in 2015.